Luforbec 100µg/6µg pMDI is indicated for adult asthma and COPD treatment, where the use of an inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) is suitable. With the same active ...

Drug firm Lupin on Friday said its unit has launched a pressurized metered dose inhaler for the treatment of asthma and ...

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is ...

Luforbec ® 100/6 (beclometasone 100mcg / formoterol 6mcg) pMDI, first branded generic alternative to Fostair ® 100/6 pMDI to treat Asthma & COPD, is now available in the UK Lupin continues their ...

Drug firm Lupin on Monday said its UK subsidiary has received approval from the regulatory authority to market Luforbec pressurised metered dose inhaler used for regular treatment of asthma in the UK ...

The drug will be available in one strength with a fixed dose to be taken once daily. (File) Lupin Limited announced on Friday that its UK subsidiary, Lupin Healthcare (UK) Limited has received ...

Drug firm Lupin on Tuesday said its UK-based arm has launched its Luforbec 100/6 dose pressurised metered dose inhaler used for the treatment of adult asthma and severe chronic obstructive pulmonary ...

Respiratory diseases affect one in five people. It is the third biggest cause of death in the UK and is a clinical priority for the NHS. Lupin's UK subsidiary, Lupin Healthcare (UK), has received the ...

Hormosan Pharma GmbH (Hormosan), Lupin’s wholly-owned subsidiary in Germany, announced the launch of Luforbec 100/6 (beclometasone 100 µg / formoterol 6 µg), a fix combination in a pressurized metered ...

Hormosan Pharma GmbH, a wholly-owned subsidiary of the company in Germany, has introduced Luforbec in the European nation, Lupin said in a statement. Find the best of Al News in one place, specially ...